ADMA Earnings
Latest Revenue124.4M
Latest Net Income37.8M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.17 | 124.4M | 37.8M | +2.0% | +21.4% |
| Q1 2026 | $0.19 | 114.5M | 45.3M | -0.3% | +72.7% |
| Q4 2025 | $0.21 | 139.2M | 49.4M | +18.4% | -55.3% |
| Q3 2025 | $0.15 | 134.2M | 36.4M | +12.0% | +0.0% |
| Q2 2025 | $0.14 | 122.0M | 34.2M | +13.8% | +0.0% |
| Q1 2025 | $0.11 | 114.8M | 26.9M | +40.2% | +37.5% |
| Q4 2024 | $0.47 | 117.5M | 111.9M | +59.1% | +687.5% |
| Q3 2024 | $0.15 | 119.8M | 35.9M | +78.1% | +1,400.0% |
| Q2 2024 | $0.14 | 107.2M | 32.1M | — | — |
| Q1 2024 | $0.08 | 81.9M | 17.8M | — | — |
| Q4 2023 | -$0.08 | 73.9M | -17645000 | — | — |
| Q3 2023 | $0.01 | 67.3M | 2.6M | — | — |
ADMA Biologics (ADMA) — Earnings